ISN Journal summaries on belimumab in lupus nephritis and deceased donation in Tamil Nadu
Kidney International® Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis Lupus nephritis is complex and difficult to treat, and clinicians need better tools to understand which patients are most likely to benefit from specific therapies. Using data from the Phase 3 BLISS-LN study, researchers assessed how belimumab affected immune...
